drugset / Trial / NCT05451095

A Study in Healthy Men to Test Whether BI 474121 Can Reverse the Memory Problems Caused by Ketamine

NCT05451095 ↗

Phase 1 Withdrawn Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

To investigate the effect of BI 474121 compared to placebo on ketamine-induced cognitive deficits to predict efficacy in patients with cognitive disorders.

Timeline

Start
2022-11-07
Primary completion
2023-06-05
Completion
2023-06-20

Outcome

Outcome not reported

Stopped: “Termination of project”

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 474121 Unknown — —

Indications

No indication recorded.